Travere Therapeutics, Inc. TVTX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Travere Therapeutics, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $491M, 100.0% of the filed sum (+110.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$491M100.0%+110.5% yoy
Members sum to the consolidated $491M for this period.
- Product$410Mshare n/a+81.1% yoy
- FILSPARI$322Mshare n/a+143.5% yoy
- Tiopronin Products$88.5Mshare n/a-6.4% yoy
- License$80.3Mshare n/a+1141.0% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Reportable Segment$127M100.0%+55.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.